Satiogen Pharmaceuticals
Latest round
- Series A
Last raised
- Apr 2008
Total raised
- $0.7M
Investors
- 1
About Satiogen Pharmaceuticals
Based in California, US, and founded in 2007, Satiogen Pharmaceuticals, Inc operates as a specialty pharma company that focuses on novel targets for treating type 2 diabetes and its metabolic mechanism therapy regulates nutrient intake and postprandial glucose. The company was Co-founded by Andrew Young and Bronislava Gedulin., a portfolio company of Deerfield Management, Frazier Healthcare Partners, and New Enterprise Associates acquired Satiogen Pharmaceuticals, Inc. from Mesa Verde Venture Partners. The company offers treatment for type 2 diabetes through the bile acid brake concept. The "Bile Acid Brake" is a metabolic regulation system that reduces food intake and postprandial hyperglycemia when bile acids accumulate in the colon and rectum. Bile acids bind to intraluminal G-protein coupled receptors on colorectal L-cells, which release a variety of metabolic hormones that regulate satiety and glucose homeostasis.
Who invested in Satiogen Pharmaceuticals
1 investor across 1 round
See all investors in Satiogen Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Apr 15, 2008
Amount
$0.7M
Investors
Questions about Satiogen Pharmaceuticals
Who invested in Satiogen Pharmaceuticals?
Satiogen Pharmaceuticals has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Satiogen Pharmaceuticals raised?
Satiogen Pharmaceuticals has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Satiogen Pharmaceuticals last raise money?
Satiogen Pharmaceuticals's most recent round on record is a Series A, in Apr 2008.
What does Satiogen Pharmaceuticals do?
Based in California, US, and founded in 2007, Satiogen Pharmaceuticals, Inc operates as a specialty pharma company that focuses on novel targets for treating type 2 diabetes and its metabolic mechanism therapy regulates nutrient intake and postprandial glucose.
Where is Satiogen Pharmaceuticals headquartered?
Satiogen Pharmaceuticals is headquartered in San Diego, US.
Which VCs invest in companies like Satiogen Pharmaceuticals?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Satiogen Pharmaceuticals's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Satiogen Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.